Aktienanalyse zu Silexion Therapeutics Corp (SLXN)SLXNSilexion Therapeutics Corp

Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected. It operates in the Healthcare sector.

Silexion Therapeutics Corp (SLXN) is not a good buy right now due to significant financial losses and poor stock performance. The current price is $0.14, which is a staggering 99.23% decline year-to-date. Additionally, the company reported a net loss of $3.55 million in Q2 2026, reflecting increased R&D expenses, and the RSI is at 34.941, indicating potential oversold conditions but not enough to warrant a buy. The main risk is the company's ongoing financial instability, with a forward P/E ratio of 0 and a price-to-book ratio of 49.72, suggesting overvaluation given its current financial state.